Published online Nov 6, 2018. doi: 10.12998/wjcc.v6.i13.650
Peer-review started: July 19, 2018
First decision: August 25, 2018
Revised: September 13, 2018
Accepted: October 11, 2018
Article in press: October 11, 2018
Published online: November 6, 2018
Processing time: 110 Days and 2.4 Hours
To determine the therapeutic effect of photodynamic therapy (PDT) for middle-advanced stage upper gastrointestinal carcinomas.
We searched PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Wanfang Database from inception to April 2018 for randomized controlled studies. These studies compared PDT with other palliative therapies (radiotherapy, chemotherapy, or Nd:YAG laser) and compared PDT, radiotherapy, or chemotherapy alone with PDT combined with chemotherapy/radiotherapy. In our meta-analysis, both fixed and random effects models were used to estimate the risk ratio (RR) for dichotomous outcomes (the response rate and one-year survival rate).
Ten random controlled clinical studies with 953 patients were included in the analysis. The effective rate for PDT was better than that of radiotherapy or Nd:YAG laser for the treatment of middle-advanced upper gastrointestinal carcinomas [RR = 1.36; 95% confidence interval (CI): 1.13-1.65; P = 0.001]. In addition, PDT combined with chemotherapy had significantly better efficacy and a higher one-year survival rate than PDT or chemotherapy alone (significant remission rate, RR = 1.62; 95%CI: 1.34-1.97; P < 0.00001; one-year survival rate, RR = 1.81; 95%CI: 1.13-2.89; P = 0.01).
PDT is a useful method for the treatment of middle-advanced stage upper gastrointestinal carcinomas. PDT combined with chemotherapy or radiotherapy can enhance its efficacy and prolong survival time.
Core tip: Photodynamic therapy (PDT) is minimally invasive compared with chemotherapy and radiotherapy for the treatment of cancers. Limited data exist regarding the efficacy of PDT alone or combined with radiotherapy and chemotherapy for the treatment of middle-advanced stage upper gastrointestinal carcinomas. Therefore, we performed a systematic review and meta-analysis of ten available randomized controlled clinical trials that addressed the efficacy of PDT alone or combined with radiotherapy and chemotherapy in patients with middle-advanced stage upper gastrointestinal carcinomas. Our analysis showed that PDT may be suitable for single or combined treatment of middle-advanced stage upper gastrointestinal carcinomas, especially for elderly patients, those with severe diseases, those with severe complications, and those unwilling to undergo surgery.